Literature DB >> 27098405

Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis.

Francesco Ciccia1, Aroldo Rizzo2, Rosario Maugeri3, Riccardo Alessandro4, Stefania Croci5, Giuliana Guggino1, Alberto Cavazza6, Stefania Raimondo4, Alessandra Cannizzaro2, Domenico Gerardo Iacopino3, Carlo Salvarani7, Giovanni Triolo1.   

Abstract

OBJECTIVES: To investigate whether artery tertiary lymphoid organs (ATLOs) are present in giant cell arteritis (GCA) and that their formation is associated with the ectopic expression of constitutive lymphoid tissue-homing chemokines.
METHODS: Reverse transcriptase PCR, immunohistochemical and immunofluorescence analysis were used to determine the presence of ectopic ATLOs in GCA and the expression of chemokines/chemokine receptors and cytokines involved in lymphoneogenesis in the temporal artery samples obtained from 50 patients with GCA and 30 controls. The presence of lymphatic conduits, of follicular dendritic cells (FDCs) precursors and lymphoid tissue inducer cells was also investigated. Finally, expression of CXCL13, B cell activating factor (BAFF), a proliferation-inducing ligand (APRIL) and CCL21 by isolated myofibroblasts was evaluated before and after stimulation with Toll-like receptors (TLRs) agonists and cytokines.
RESULTS: ATLOs were observed in the media layer of 60% of patients with GCA in close proximity to high endothelial venules and independently by the age of patients and the presence of atherosclerosis. ATLO formation was also accompanied by the expression of CXCL13, BAFF, a proliferation-inducing ligand (APRIL), lymphotoxin (LT)-β, interleukin (IL)-17 and IL-7, the presence of FDC precursors and of lymphoid conduits. Stimulation of myofibroblasts with TLR agonists and cytokines resulted in the upregulation of BAFF and CXCL13.
CONCLUSIONS: ATLOs occur in the inflamed arteries of patients with GCA possibly representing the immune sites where immune responses towards unknown arterial wall-derived antigens may be organised. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Chemokines; Cytokines; Giant Cell Arteritis

Mesh:

Substances:

Year:  2016        PMID: 27098405     DOI: 10.1136/annrheumdis-2016-209217

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

1.  Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials.

Authors:  Marit M Melssen; Karlyn E Pollack; Max O Meneveau; Mark E Smolkin; Joel Pinczewski; Alexander F Koeppel; Stephen D Turner; Katia Sol-Church; Alexandra Hickman; Donna H Deacon; Gina R Petroni; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2021-01-16       Impact factor: 6.968

Review 2.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.

Authors:  Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

3.  Genome-Wide DNA Methylation Profiling in CD8 T-Cells and Gamma Delta T-Cells of Asian Indian Patients With Takayasu Arteritis.

Authors:  Jayakanthan Kabeerdoss; Debashish Danda; Ruchika Goel; Hindhumathi Mohan; Sumita Danda; R Hal Scofield
Journal:  Front Cell Dev Biol       Date:  2022-06-23

4.  CD4 T lymphocyte autophagy is upregulated in the salivary glands of primary Sjögren's syndrome patients and correlates with focus score and disease activity.

Authors:  Cristiano Alessandri; Francesco Ciccia; Roberta Priori; Elisa Astorri; Giuliana Guggino; Riccardo Alessandro; Aroldo Rizzo; Fabrizio Conti; Antonina Minniti; Cristiana Barbati; Marta Vomero; Monica Pendolino; Annacarla Finucci; Elena Ortona; Tania Colasanti; Marina Pierdominici; Walter Malorni; Giovanni Triolo; Guido Valesini
Journal:  Arthritis Res Ther       Date:  2017-07-25       Impact factor: 5.156

5.  Incomplete Freund's adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment.

Authors:  Karlyn E Pollack; Max O Meneveau; Marit M Melssen; Kevin T Lynch; Alexander F Koeppel; Samuel J Young; Stephen Turner; Pankaj Kumar; Katia Sol-Church; Ileana S Mauldin; Craig L Slingluff
Journal:  J Immunother Cancer       Date:  2020-04       Impact factor: 13.751

6.  β-amyloid wall deposit of temporal artery in subjects with spontaneous intracerebral haemorrhage.

Authors:  Antonino Tuttolomondo; Rosario Maugeri; Elisabetta Orlando; Giulio Giannone; Francesco Ciccia; Aroldo Rizzo; Domenico Di Raimondo; Francesca Graziano; Rosaria Pecoraro; Carlo Maida; Irene Simonetta; Anna Cirrincione; Francesca Portelli; Francesca Corpora; Domenico Gerardo Iacopino; Antonio Pinto
Journal:  Oncotarget       Date:  2018-10-05

7.  Identification of key genes and pathways contributing to artery tertiary lymphoid organ development in advanced mouse atherosclerosis.

Authors:  Xi Zhang; Fayuan Liu; Peng Bai; Nianguo Dong; Chong Chu
Journal:  Mol Med Rep       Date:  2019-02-15       Impact factor: 2.952

Review 8.  Understanding Immune Cells in Tertiary Lymphoid Organ Development: It Is All Starting to Come Together.

Authors:  Gareth W Jones; David G Hill; Simon A Jones
Journal:  Front Immunol       Date:  2016-10-03       Impact factor: 7.561

Review 9.  Role of CXCL13 in the formation of the meningeal tertiary lymphoid organ in multiple sclerosis.

Authors:  Ana C Londoño; Carlos A Mora
Journal:  F1000Res       Date:  2018-04-27

Review 10.  Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?

Authors:  Kornelis S M van der Geest; Maria Sandovici; Yannick van Sleen; Jan-Stephan Sanders; Nicolaas A Bos; Wayel H Abdulahad; Coen A Stegeman; Peter Heeringa; Abraham Rutgers; Cees G M Kallenberg; Annemieke M H Boots; Elisabeth Brouwer
Journal:  Arthritis Rheumatol       Date:  2018-07-30       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.